|Quantity Discounts||1 - 9999|
|1 - 9999|
|1 - 9999|
|1 - 9999|
Last August, Pfizer agreed to pay $60 million for illegal payments made by its subsidiaries to foreign officials to obtain regulatory approvals, sales and prescriptions for its products.
For the past two years, industry groups have called for a new detailed written Foreign Corrupt Practices Act (FCPA) guidance. Heeding their calls, in November 2012 the DOJ and SEC released a 130-page resource guide.
The guidance breaks new ground and clarifies lingering concerns regarding:
Here’s how to overcome this latest compliance challenge while doing business internationally. With this encore presentation you can gain piece of mind in understanding the most comprehensive FCPA guidance.
In light of the new guidance from DOJ and the SEC, companies should consider re-evaluating their current FCPA compliance programs.
Now, more than ever, you need expert opinion regarding how DOJ and the SEC have exercised their prosecutorial discretion, how they might treat numerous hypothetical situations, and how they interpret key sections of the FCPA.
Noted attorney Keith Korenchuk of Arnold & Porter LLP shares with you his proactive, proven plan for FCPA compliance. You will come away from this encore presentation with all you need to successfully understand:
And like every FDAnews encore presentation, Foreign Corrupt Practices Act is convenient to attend. All that’s required is that you be in front of a screen at the appointed time, whether you’re at the office or telecommuting from your office-in-home.
While the guide may clarify many issues regarding how DOJ and the SEC exercise their prosecutorial discretion, it does not make FCPA compliance any easier.
Compliance and due diligence are becoming increasingly complex as companies are facing increasingly divergent regulatory environments in the different jurisdictions where they do business. Get your proactive FCPA plan in place before it’s too late.
This encore presentation is a must for professionals in drug, biotech, device, biologics and diagnostics companies, including:
Keith Korenchuk, partner with Arnold & Porter, LLP, counsels and advises global companies on regulatory and compliance matters worldwide, with a focus on compliance program effectiveness, compliance program implementation, operations and evaluation, and related regulatory counseling and advice. He works in a wide variety of industries and sectors, including consumer products, electronics, energy, financial services, life sciences, medical devices, pharmaceuticals, and technology.
Mr. Korenchuk's prior experience includes serving as the CEO of a company that focused on pharmaceutical and healthcare sector compliance, as well as the CEO of a research and development company that focused on homeland security technologies. Since 2001, Mr. Korenchuk has been included in The Best Lawyers in America® and holds an M.P.H. from Harvard and a J.D. from the University of Virginia.
Samuel Witten, counsel with Arnold & Porter, LLP has an extensive background in international law, the development and implementation of corporate compliance programs, international dispute settlement, and international law enforcement cooperation. Before joining Arnold & Porter, he served in the U.S. Department of State for 22 years, including 19 years in the Office of the Legal Adviser where he was Deputy Legal Adviser from 2001-2007. He also held three senior State Department foreign policy positions, including Acting Assistant Secretary of State, where he managed the State Department's international refugee assistance programs and the resettlement of refugees into the United States.
Mr. Witten helps companies develop and implement compliance programs and corrective actions related to the Foreign Corruption Practices Act, the UK Bribery Act, and other legislation. He advises companies on issues of corporate social responsibility. He also represents domestic and international clients in litigation and arbitrations and in domestic enforcement and regulatory matters, and has represented foreign governments in dispute resolution and public international law matters. His practice also includes economic sanctions and issues relating to international law enforcement cooperation.
|Date:||Jan. 21 – Feb. 8, 2013|
|Location:||Your office or conference room (no need to travel!)|
Gather your team for maximum benefit! Your investment is for one dial-in.
Significant tuition discounts are available for three or more sites from
Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally
We accept American Express, Visa and MasterCard. Make checks payable to FDAnews.
Or, register by phone: toll free (888) 838-5578 (inside the U.S.) or +1 (703) 538-7600
Registrations may not be cancelled. Please contact customer service to make any substitutions.
Interested in Becoming a Speaker?
We're always looking for industry leaders eager to share their expertise at an FDAnews audioconference, webinar or physical conference. Our seasoned speaker community includes executives in the pharmaceutical, medical device and clinical trial industries, regulatory affairs, quality control, compliance, healthcare and academia, as well as several former — and current — top FDA officials. Click here to complete our speaker opportunity form and have a representative contact you about future opportunities.
Copyright ©2018. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing